Abstract
Refemitanil is an ultra-short-acting opioid analgesic. It is metabolized by non-specific esterase in the blood and tissues, and therefore metabolism of it does not depend on liver/kidney function. If the dose of remifentanil were calculated by total body weight, extremely obese patients would receive an overdose. Since remifentanil is a short-acting agent, we should take care of postoperative analgesia.
